These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34341160)

  • 1. Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence.
    Mayer SL; Fields ME; Hulbert ML
    Neoreviews; 2021 Aug; 22(8):e531-e539. PubMed ID: 34341160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Kassim AA; DeBaun MR
    Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
    Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
    Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
    [No Abstract]   [Full Text] [Related]  

  • 4. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
    DeBaun MR
    Blood; 2020 May; 135(22):1997-1999. PubMed ID: 32282033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
    Chaturvedi S; DeBaun MR
    Am J Hematol; 2016 Jan; 91(1):5-14. PubMed ID: 26547630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
    Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
    Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia.
    DeBaun MR
    J Pediatr; 2005 Oct; 147(4):560-1. PubMed ID: 16227052
    [No Abstract]   [Full Text] [Related]  

  • 9. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 10. Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
    Sánchez LM; Nieves RM; Latham T; Stuber S; Luden JR; Urcuyo GS; Berges ME; Florencio C; Gonzalez C; Del Villar P; Lane A; Schultz W; Jeste N; Mena R; Ware RE
    Blood Adv; 2018 Nov; 2(Suppl 1):50-53. PubMed ID: 30504201
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in management of sickle cell disease.
    Agarwal MB
    Indian J Pediatr; 2003 Aug; 70(8):649-54. PubMed ID: 14510086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
    Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sickle cell disease clinical phenotypes in children from South-Western, Nigeria.
    Adegoke SA; Adeodu OO; Adekile AD
    Niger J Clin Pract; 2015; 18(1):95-101. PubMed ID: 25511352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for primary stroke prevention in children with sickle cell anaemia.
    Jordan LC; Casella JF; DeBaun MR
    Br J Haematol; 2012 Apr; 157(1):14-25. PubMed ID: 22224940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease.
    Mack AK; Thompson AA
    J Pediatr Health Care; 2017; 31(2):145-154. PubMed ID: 27423528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis.
    Hasson C; Veling L; Rico J; Mhaskar R
    Medicine (Baltimore); 2019 Dec; 98(51):e18225. PubMed ID: 31860969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A; Ware RE; Thornburg CD
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea.
    Lagunju IA; Brown BJ; Sodeinde OO
    Niger Postgrad Med J; 2013 Sep; 20(3):181-7. PubMed ID: 24287747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sickle cell disease--pathophysiology and treatment.
    Redding-Lallinger R; Knoll C
    Curr Probl Pediatr Adolesc Health Care; 2006; 36(10):346-76. PubMed ID: 17055417
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.
    Mulaku M; Opiyo N; Karumbi J; Kitonyi G; Thoithi G; English M
    Arch Dis Child; 2013 Nov; 98(11):908-14. PubMed ID: 23995076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.